Melanoma



LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma


Condition:   Melanoma
Interventions:   Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company
Not yet recruiting - verified April 2017


SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients


Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Radiation: SAbR;   Drug: Ipilimumab;   Drug: Nivolumab
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting - verified April 2017


Tracing Dissemination of Melanoma Cells in Healthy Tissues


Condition:   Melanoma
Intervention:   Procedure: Melanoma and peritumoral skin excision
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting - verified July 2016


Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions


Condition:   Melanoma
Interventions:   Drug: MRX34;   Drug: Dexamethasone
Sponsor:   Mirna Therapeutics, Inc.
Withdrawn - verified July 2016


Prospective Melanoma Database


Condition:   Melanoma
Intervention:   Other: clinical biological data collection on melanoma
Sponsor:   Institut Claudius Regaud
Recruiting - verified July 2016


BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: BGB324+pembrolizumab;   Drug: BGB324+dabrafenib and trametinib;   Drug: pembrolizumab;   Drug: dabrafenib and trametinib
Sponsors:   Haukeland University Hospital;   BerGenBio ASA
Recruiting - verified January 2017


A Clinical Trial of Patients With Melanoma


Condition:   Melanoma
Interventions:   Drug: Digoxin Combination;   Drug: Dabrafenib;   Drug: Trametinib
Sponsor:   University of Texas Southwestern Medical Center
Recruiting - verified November 2016


A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)


Condition:   Melanoma
Interventions:   Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
Sponsors:   Incyte Corporation;   Merck Sharp & Dohme Corp.
Recruiting - verified April 2017


Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma


Condition:   Malignant Melanoma
Intervention:  
Sponsor:   Universitair Ziekenhuis Brussel
Recruiting - verified September 2016


Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas


Condition:   Melanoma
Intervention:   Radiation: Protontherapy
Sponsor:   Centre Antoine Lacassagne
Recruiting - verified June 2016


Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)


Condition:   Melanoma
Intervention:  
Sponsors:   Daniel Gareau;   Oregon Health and Science University;   University of California, Irvine
Recruiting - verified August 2016


Melanoma Perception and Health Literacy in People of Color


Condition:   Melanoma
Interventions:   Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
Sponsor:   Northwestern University
Completed - verified November 2016


Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy


Condition:   Melanoma
Intervention:   Drug: regorafenib
Sponsor:   Yonsei University
Recruiting - verified January 2017


Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma


Condition:   Melanoma
Interventions:   Drug: All-Trans Retinoic Acid;   Drug: Ipilimumab
Sponsor:   University of Colorado, Denver
Active, not recruiting - verified February 2017


Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients


Condition:   Melanoma
Interventions:   Drug: Dabrafenib;   Drug: Trametinib;   Drug: Metformin
Sponsors:   James Graham Brown Cancer Center;   University of Louisville
Recruiting - verified November 2016


LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma


Condition:   Melanoma
Interventions:   Drug: LGX818;   Drug: MEK162;   Drug: LEE011;   Drug: BGJ398;   Drug: BKM120;   Drug: INC280
Sponsor:   Array BioPharma
Active, not recruiting - verified March 2017


Treatment of Advanced Melanoma With MK-3475 and Peginterferon


Condition:   Melanoma
Interventions:   Drug: MK-3475;   Drug: Peginterferon alfa-2b
Sponsors:   Hassane M. Zarour, MD;   Merck Sharp & Dohme Corp.;   Melanoma Research Alliance
Recruiting - verified July 2016


A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma


Condition:   Melanoma
Interventions:   Biological: Poly-ICLC;   Biological: Peptides
Sponsor:   Patrick Ott, MD
Recruiting - verified September 2016


In Vivo Real-time Detection of Circulating Melanoma Cells


Condition:   Melanoma
Intervention:  
Sponsor:   University of Arkansas
Recruiting - verified August 2016


Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma


Condition:   Melanoma
Interventions:   Drug: Talimogene laherparepvec plus ipilimumab;   Drug: Ipilimumab
Sponsor:   Amgen
Active, not recruiting - verified February 2017


A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients


Condition:   Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Metformin
Sponsors:   James Graham Brown Cancer Center;   University of Louisville
Recruiting - verified November 2016


Sun Exposure and Melanoma in Agricultural Workers


Condition:   Melanoma
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 25, 2017


The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma


Condition:   Metastatic Melanoma
Intervention:   Biological: DC/tumor fusion vaccine
Sponsors:   Beth Israel Deaconess Medical Center;   Genzyme, a Sanofi Company
Completed - verified March 2017


Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma


Condition:   Melanoma
Interventions:   Drug: hu14.18-IL2;   Drug: hu14.18-IL2
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   EMD Serono
Active, not recruiting - verified June 2016


Vaccination Plus Ontak in Patients With Metastatic Melanoma


Condition:   Melanoma
Interventions:   Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
Sponsors:   University of Chicago;   Eisai Inc.
Active, not recruiting - verified August 2016

Refine Your Search Advanced Search